Showing results (41-50 of 157) with videos related to

Sort By:
Pageof 16
Clinical and Experimental Rheumatology|April 30, 2013
Achieving remission in clinical practice: lessons from clinical trial dataVivian P Bykerk, Edward C Keystone, Bindee Kuriya, et al.
Rheumatology (Oxford, England)|October 20, 2019
An open-label randomized controlled trial of DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDsJanet Pope, Emmanouil Rampakakis, Julie Vaillancourt, et al.
Rheumatology and Therapy|March 13, 2019
Tocilizumab Patterns of Use, Effectiveness, and Safety in Patients with Rheumatoid Arthritis: Final Results from a Set of Multi-National Non-Interventional StudiesBoulos Haraoui, Gustavo Casado, László Czirják, et al.
Clinical Rheumatology|December 18, 2008
Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritisAnthony Russell, Ariel Beresniak, Louis Bessette, et al.
Annals of the Rheumatic Diseases|August 28, 2013
The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritisJanet E Pope, Boulos Haraoui, J Carter Thorne, et al.
Rheumatology and Therapy|December 19, 2022
Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus MethotrexateRoy Fleischmann, Boulos Haraoui, Maya H Buch, et al.
The Open Rheumatology Journal|January 4, 2018
Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA StudyCarter Thorne, Gilles Boire, Andrew Chow, et al.
The Journal of Rheumatology|April 15, 2023
Factors Associated With Maintenance of Remission Following Change From Combination Therapy to Monotherapy in Patients With Rheumatoid ArthritisJeffrey R Curtis, Paul Emery, Greg Kricorian, et al.
Rheumatology (Oxford, England)|August 15, 2019
Experience with tofacitinib in Canada: patient characteristics and treatment patterns in rheumatoid arthritis over 3 yearsJanet Pope, Louis Bessette, Niall Jones, et al.
Clinical Therapeutics|June 6, 2022
Impact of Methotrexate Discontinuation, Interruption, or Persistence in US Patients with Rheumatoid Arthritis Initiating Tofacitinib + Oral Methotrexate CombinationStanley B Cohen, Boulos Haraoui, Jeffrey R Curtis, et al.
Pageof 16